Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior.

@article{Hanks1996PretreatmentPA,
  title={Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior.},
  author={Gerald E. Hanks and Alexandra L. Hanlon and William R. Lee and A Slivjak and Timothy E. Schultheiss},
  journal={International journal of radiation oncology, biology, physics},
  year={1996},
  volume={34 3},
  pages={549-53}
}
PURPOSE The distribution of pretreatment and posttreatment prostate specific antigen (PSA) doubling times (PSADT) varies widely. This report examines the pretreatment PSADT as an independent predictor of biochemical freedom from disease (bNED) and describes the clinical utility of PSADT. METHODS AND MATERIALS Ninety-nine patients with T1-3 NX, M-0 prostate cancer treated between February 1989 and November 1993 have pretreatment PSADTs calculated from three or more PSA levels. Biochemical… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…